Isocitrate dehydrogenase mutations in gliomas: Mechanisms, biomarkers and therapeutic target

Current Opinion in Neurology

Volumn 24, Issue 6, 2011, Pages 648-652

  Guo, Changcun ^a,b,c   Pirozzi, Christopher J ^a,b   Lopez, Giselle Y ^a,b   Yan, Hai ^a,b  

^a DUKE CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

glioma; isocitrate dehydrogenase; somatic mutation

Indexed keywords

2 HYDROXYGLUTARIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE;

AMINO ACID SUBSTITUTION; APOPTOSIS; CANCER SURVIVAL; DNA METHYLATION; ENZYME ACTIVITY; GENE ACTIVITY; GENE MUTATION; GENETIC ASSOCIATION; GLIOMA; OXIDATIVE STRESS; REVIEW;

BIOLOGICAL MARKERS; BRAIN NEOPLASMS; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; ISOCITRATES; ISOENZYMES; KETOGLUTARIC ACIDS; POINT MUTATION; PROGNOSIS; PROTEIN CONFORMATION;

EID: 81855213133     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32834cd415     Document Type: Review

References (60)

1. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1812.
2. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174:1149-1153.
3. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-773.
4. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28:3636-3643.
5. Schnittger S, Haferlach C, Ulke M, et al. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010; 116:5486-5496.
6. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361:1058-1066.
7. Hemerly JP, Bastos AU, Cerutti JM. Identification of several novel nonp.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol 2010; 163:747-755.
8. Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009; 30:7-11.
9. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009; 125:353-355.
10. Lopez GY, Reitman ZJ, Solomon D, et al. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem Biophys Res Commun 2010; 398:585-587.
11. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-274. (Pubitemid 44571966)
12. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1(R132) mutation is associated with reduced NADP\+-dependent IDH activity in glioblastoma. Acta Neuropathol 2010; 119:487-494.
13. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261-265.
14. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19:17-30.
15. Metellus P, Colin C, Taieb D, et al. IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neurooncol 2011 [Epub ahead of print].
16. Williams SC, Karajannis MA, Chiriboga L, et al. R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1alpha upregulation in adult glioma. Acta Neuropathol 2011; 121:279-281.
17. Jin G, Reitman ZJ, Spasojevic I, et al. 2-Hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One 2011; 6:e16812.
18. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462:739-744.
19. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alphaketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17:225-234.
20. Yang B, Zhong C, Peng Y, et al. Molecular mechanisms of 'off-on switch' of activities of human IDH1 by tumor-associated mutation R132H. Cell Res 2010; 20:1188-1200.
21. Pietrak B, Zhao H, Qi H, et al. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of alphaHG. Biochemistry 2011; 50:4804-4812.
22. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17:510-522.
23. Christensen BC, Smith AA, Zheng S, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 2011; 103:143-153.
24. Laffaire J, Everhard S, Idbaih A, et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol 2011; 13:84-98.
25. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553-567.
26. Ito S, D'Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466:1129-1133.
27. Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011; 12:463-469.
28. Yang ES, Park JW. Knockdown of cytosolic NADP(\+)-dependent isocitrate dehydrogenase enhances MPP(\+)-induced oxidative injury in PC12 cells. BMB Rep 2011; 44:312-316.
29. Ronnebaum SM, Ilkayeva O, Burgess SC, et al. A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. J Biol Chem 2006; 281:30593-30602. (Pubitemid 44582115)
30. Kil IS, Chung KH, Park JW. Silencing of mitochondrial NADP\+-dependent isocitrate dehydrogenase gene enhances selenite-induced apoptosis. Free Radic Res 2010; 44:332-339.
31. Shin SW, Kil IS, Park JW. Silencing of mitochondrial NADP\+-dependent isocitrate dehydrogenase by small interfering RNA enhances heat shockinduced apoptosis. Biochem Biophys Res Commun 2008; 366:1012-1018.
32. Jung KH, Park JW. Suppression of mitochondrial NADP(\+)-dependent isocitrate dehydrogenase activity enhances curcumin-induced apoptosis in HCT116 cells. Free Radic Res 2011; 45:431-438.
33. McDonald KL, McDonnell J, Muntoni A, et al. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 2010; 69:729-736.
34. Korshunov A, Meyer J, Capper D, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009; 118:401-405.
35. Camelo-Piragua S, Jansen M, Ganguly A, et al. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol 2011; 70:110-115.
36. Horbinski C, Kofler J, Yeaney G, et al. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol 2011; 21:564-574.
37. Narasimhaiah D, Miquel C, Verhamme E, et al. IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri. Neuropathology 2011; doi: 10.1111/j.1440-1789.2011.01216.x [Epub ahead of print].
38. Seiz M, Tuettenberg J, Meyer J, et al. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol 2010; 120:261-267.
39. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progressionfree and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27:5743-5750.
40. Bujko M, Kober P, Matyja E, et al. Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients. Mol Diagn Ther 2010; 14:163-169.
41. Metellus P, Coulibaly B, Colin C, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010; 120:719-729.
42. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27:4150-4154.
43. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009; 118:469-474.
44. Pollack IF, Hamilton RL, Sobol RW, et al. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst 2011; 27:87-94.
45. Antonelli M, Buttarelli FR, Arcella A, et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol 2010; 99:209-215.
46. Desestret V, Ciccarino P, Ducray F, et al. Prognostic stratification of gliomatosis cerebri by IDH1(R132H) and INA expression. J Neurooncol 2011 [Epub ahead of print].
47. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75:1560-1566.
48. Taal W, Dubbink HJ, Zonnenberg CB, et al. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro Oncol 2011; 13:235-241.
49. Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009; 73:1792-1795.
50. Van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16:1597-1604.
51. Felsberg J, Wolter M, Seul H, et al. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 2010; 119:501-507.
52. Capper D, Sahm F, Hartmann C, et al. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 2010; 34:1199-1204.
53. Chou WC, Huang YN, Huang CF, et al. A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations. Blood 2010; 116:495-496.
54. Meyer J, Pusch S, Balss J, et al. PCR-and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 2010; 20:298-300.
55. Boisselier B, Marie Y, Labussiè re M, et al. COLD PCR HRM: a highly sensitive detection method for IDH1 mutations. Hum Mutat 2010; 31:1360-1365.
56. Horbinski C, Kelly L, Nikiforov YE, et al. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn 2010; 12:487-492.
57. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207:339-344.
58. Sahm F, Capper D, Pusch S, et al. Detection of 2-hydroxyglutarate in formalinfixed paraffin-embedded glioma specimens by gas-chromatography/ massspectrometry. Brain Pathol 2011 [Epub ahead of print].
59. Nagarajan R, Thomas MA, Pope WB, et al. Detection of 2-hydroxyglutarate in mutant brain tumors in vivo using proton magnetic resonance spectroscopy [abstract]. Proc Intl Soc Mag Reson Med 2011; 19:184.
60. Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010; 70:8981-8987.